论文部分内容阅读
目的探讨EZH2和CTGF基因在肾透明细胞癌中的表达及其临床意义。方法用逆转录-聚合酶链反应(RT-PCR)和免疫组织化学法分别检测肾透明细胞癌标本(50例)及相应癌旁肾组织中EZH2和CTGF基因在mR-NA和蛋白水平的表达。结果与癌旁组织相比,肾癌组织中EZH2基因在mRNA和蛋白水平表达均升高(P<0.01),而CTGF的表达水平均降低(P<0.01);肾透明细胞癌中EZH2升高和CTGF降低的程度与临床分期相关(P<0.05),与病理分化程度、性别、年龄等的关系无统计学差异(P>0.05)。结论 EZH2和CTGF参与了肾透明细胞癌的发生和发展,EZH2可能成为肾透明细胞癌一个潜在的基因治疗靶点。
Objective To investigate the expression of EZH2 and CTGF in renal clear cell carcinoma and its clinical significance. Methods The expressions of EZH2 and CTGF mRNA in renal clear cell carcinoma (50 cases) and their corresponding paracancer tissues were detected by RT-PCR and immunohistochemistry respectively at mR-NA and protein levels . Results Compared with the adjacent non-cancerous tissues, the expression of EZH2 mRNA and protein in renal cell carcinoma was significantly increased (P <0.01), while the expression of CTGF was lower (P <0.01), and the expression of EZH2 in renal clear cell carcinoma (P <0.05). There was no significant difference between CTGF and CTGF in clinical stage (P <0.05) and pathological grade, sex, age and so on (P> 0.05). Conclusion EZH2 and CTGF are involved in the development of renal clear cell carcinoma. EZH2 may be a potential gene therapy target for clear cell renal cell carcinoma.